Label Image (Lbl500905760)
Levetiracetam
Product Images NDC 50090-5760
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-5760). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
This is a figure (Figure 1) depicting the Responder Rate in Study 1 with a reduction of 250% from baseline. It shows a graph with percentages ranging from 0% to 39.6%, and two different treatments, Leviaseam 100 and Leviaseam 000, both of which are statistically significant versus placebo.*
Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
This is a figure from a medical study, showing the responder rate (250% reduction from baseline) in Study 2 period A. The figure displays the percentage of patients who responded to the treatment on the Y-axis, ranging from 0% to 40%. The X-axis shows the three groups of patients: placebo (N=111), Levetiracetam 1000 mg/day (N=106), and Levetiracetam 2000 mg/day (N=105). The asterisk (*) indicates that the difference between the groups taking Levetiracetam 2000 mg/day and placebo was statistically significant.*
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
This is a statistical figure from Study 3 showing the responder rate (>50% reduction from baseline) for a certain treatment. The placebo group (with 104 individuals) had a responder rate of 14.4%, while the group treated with 3000 mg/day of Levetiracetam (with 180 individuals) had a responder rate of 45%, which is considered statistically significant compared to the placebo group.*
Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
The text describes a figure (Figure 4) that shows the responder rate in Study 4 where the percentage of reduction from baseline is 250%. There are two bars in the figure representing the placebo (N=97) and Levetiracetam (N=101) groups. The Levetiracetam group had a statistically significant result when compared to the placebo group. The text does not provide any additional information.*
Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
The figure shows the Responder Rate for patients between 1 month to less than 4 years old, with a reduction of over 50% from the baseline in Study 5. The percentage of responders is 190.6% for those treated with Lovetracatam and 0% for those who received placebo. Lovetracatam showed a statistically significant improvement compared to placebo.*
Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
The image shows the responder rate for PGTC seizure frequency per week in Study 7, indicating that Levetiracetam was statistically significant versus placebo with a 250% Reduction from Baseline. The graph shows that 72.2% of patients in the Levetiracetam group had a 50% or higher reduction in seizure frequency, compared to 45.2% in the placebo group. The image also shows the number of patients in each group and the percentage of responders.*
Chemical Structure (Levetiracetam Str)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
